Primary pancreatic sarcomas

Primary pancreatic sarcomas are extremely rare malignant mesenchymal neoplasms arising from non-epithelial tissues of the pancreatic gland, such as smooth muscle, connective stroma, vascular endothelium or interstitial cells with a stromal phenotype. They account for an exceptional proportion of pancreatic neoplasms and constitute a distinct category from ductal adenocarcinoma and neuroendocrine tumors in both biology and diagnostic-therapeutic pathway. Their rarity means that much of the information comes from registries, retrospective analyses and limited case series, requiring a rigorous approach to establishing primary origin and excluding pancreatic metastases from sarcomas arising elsewhere.

Clinically, presentation often overlaps that of other pancreatic masses and includes abdominal pain, weight loss, nausea, a sensation of fullness and, less frequently, obstructive jaundice when the lesion involves the pancreatic head. In some histologic types, a necrotic-hemorrhagic component may cause anemia or rapid worsening of symptoms. Diagnosis requires integration of high-quality imaging and adequate tissue sampling, because morphology may mimic undifferentiated carcinoma, solid-cystic tumors, extragastrointestinal GIST, lymphoma or poorly differentiated neuroendocrine neoplasms. Immunohistochemistry and, when necessary, molecular diagnostics are central to defining the histologic type, identifying fusions or driver alterations and guiding treatment decisions.

Treatment is typically multimodal and depends on histologic type, grade, resectability and the presence of metastases. When disease is localized and resectable, surgery with negative margins has the greatest prognostic impact, often combined with systemic strategies based on principles for visceral sarcomas. In advanced disease, systemic therapy and, in selected settings, radiotherapy or targeted locoregional procedures have a role in controlling disease and symptoms. Optimal management requires multidisciplinary assessment at centers experienced in sarcoma and pancreatic tumors because correct histologic classification, resection planning and systemic-regimen selection directly affect outcome.

The epidemiology of primary pancreatic sarcomas is dominated by their extreme rarity. In oncology registry series, pancreatic sarcomas account for a minimal fraction of primary tumors of the gland, with a heterogeneous histologic distribution. Reported types include leiomyosarcoma, angiosarcoma, synovial sarcoma, small round-cell sarcomas including the extraosseous Ewing/PNET spectrum, undifferentiated sarcomas and, more broadly, extragastrointestinal stromal tumors (EGIST) that may present as pancreatic masses and require careful differential assessment. The relative frequency of individual types varies among series and also depends on inclusion criteria and the accuracy of pathologic review.

Age at diagnosis varies and reflects the histologic type. Some entities, such as leiomyosarcoma, tend to present in adulthood or older age, whereas tumors with specific molecular features, such as synovial sarcoma or extraosseous Ewing sarcoma, may occur in younger patients. No consistent sex pattern is evident, also because of the small numbers. The tumor may arise in the head, body or tail, with obstructive jaundice occurring in head lesions and more vague symptoms in body-tail lesions.

The etiologic causes of primary pancreatic sarcomas are undefined. No exposure has been shown to be necessary and sufficient for these neoplasms to arise. Clinical attention therefore focuses on general or associative risk factors, which in most cases remain hypotheses not robustly demonstrated for the pancreatic site specifically.

Some factors are more firmly discussed for sarcomas in general and may have conceptual relevance to visceral sites, although they do not permit reliable individual risk stratification. Exposure to ionizing radiation is a recognized risk factor for secondary sarcomas at various sites, but a link with the pancreas as the primary site remains exceptionally rare. Immunosuppression and certain genetic syndromes predisposing to sarcoma may increase the risk of mesenchymal neoplasms; in practice, however, pancreatic sarcomas are more often sporadic and not associated with a clear hereditary syndrome.

Overall, rarity makes targeted preventive strategies impracticable. The clinical priority remains prompt recognition and correct classification of a pancreatic mass because the most frequent error is attribution to ductal carcinoma or another more common neoplasm, resulting in a suboptimal treatment pathway.

For primary pancreatic sarcomas, there are no screening programs or population surveillance strategies are available. Extreme rarity, absence of a specific biomarker and lack of a sufficiently accurate noninvasive test make any screening approach unsustainable and unfavorable in its risk-benefit balance.

In clinical practice, diagnosis results from a pathway guided by symptoms, incidental findings or assessment of warning signs. Pancreatic masses are frequently identified by ultrasonography, CT or MRI performed for other reasons. When a lesion has features atypical for ductal adenocarcinoma, such as very large size, expansive growth, marked hemorrhagic or necrotic components, hypervascularity or behavior inconsistent with common patterns, a mesenchymal neoplasm enters the differential diagnosis and prompts appropriate tissue sampling.

A separate setting concerns patients with a known sarcoma at another site, in whom the pancreas may harbor metastases. Surveillance in these cases follows the protocol for the primary sarcoma, and a pancreatic lesion requires targeted assessment because erroneous attribution to a pancreatic primary may substantially change strategy and prognosis. The practical objective is to accurately distinguish a metastasis, a second neoplasm and a primary pancreatic sarcoma by integrating clinical history, imaging and histologic-molecular data.

In summary, early identification depends on diagnostic appropriateness when faced with a pancreatic mass and rapid access to EUS-guided biopsy or other sampling techniques rather than systematic surveillance.

The biology of primary pancreatic sarcomas is heterogeneous because it reflects a group of distinct histologic types, each with its own molecular determinants and clinical behavior. Pathogenesis may arise from malignant transformation of resident or perivascular mesenchymal cells, smooth-muscle elements of vascular and ductal structures, vascular endothelium or stromal cells with an interstitial phenotype. In an organ dominated by exocrine and endocrine parenchyma, this mesenchymal origin explains both rarity and difficulty of early recognition.

Histologically, certain recurring patterns are particularly relevant in practice. Leiomyosarcoma shows a spindle-cell proliferation with smooth-muscle differentiation and a typical immunophenotype, including smooth-muscle actin and desmin positivity in appropriate settings, with variable but often high aggressiveness in visceral forms. Angiosarcoma displays vasoformative or solid patterns with marked endothelial atypia, necrosis and a tendency to hemorrhage; endothelial markers such as CD31 and ERG support confirmation. Synovial sarcoma, although rare in the pancreas, is defined by a characteristic fusion alteration and may mimic other spindle-cell lesions; demonstration of the specific rearrangement by molecular methods is often decisive. Tumors of the extraosseous Ewing/PNET spectrum may occur in the pancreas particularly in young people and show small round-cell morphology with supportive markers and molecular confirmation. Undifferentiated or pleomorphic sarcomas also occur, in which diagnosis is often one of exclusion after a broad immunohistochemical panel and expert review.

A subset of pancreatic masses with a stromal phenotype falls within the spectrum of extragastrointestinal GIST (EGIST) or GIST arising from contiguous structures and mimicking a pancreatic origin. In these cases, KIT (CD117) and DOG1 positivity and assessment of KIT or PDGFRA mutations have diagnostic and therapeutic value. Distinguishing a “primary pancreatic” EGIST from an adjacent GIST with secondary involvement is not always straightforward and requires pathologic-radiologic and surgical correlation.

Recurring biological features with practical impact in pancreatic sarcomas

• Molecular heterogeneity: some histologic types are defined by fusions or driver alterations, whereas others show broader genomic instability.
• Value of integrated diagnosis: morphology and immunohistochemistry provide direction, but molecular confirmation is often decisive in rare spindle-cell lesions.
• Therapeutic implications: actionable alterations are more characteristic of selected subgroups such as GIST/EGIST, whereas many visceral sarcomas require class-based systemic approaches.
• Microenvironment and vascularization: in histologic types such as angiosarcoma, hemorrhage and necrosis influence clinical presentation and complications.

Pathophysiologically, visceral sarcomas tend to grow expansively and often become large before diagnosis because the retroperitoneum and pancreatic region permit relatively silent enlargement. This favors late presentations with compression of adjacent structures, vascular involvement or local infiltration. Invasion and dissemination occur hematogenously with a frequency that varies by histologic type, whereas nodal involvement is generally less common in sarcomas than in carcinomas, although it may occur in specific entities and advanced settings.

Correct histologic classification is also fundamental because prognosis is not uniform. Some histologic types may behave relatively indolently when completely resected and low grade, whereas others, such as angiosarcoma or high-grade sarcomas, show rapid progression and early metastasis. Histologic grading, necrosis, mitotic index and surgical-margin quality are cross-cutting determinants that influence recurrence risk and outcome.

The clinical manifestations of primary pancreatic sarcomas are largely nonspecific and depend on site, size, relationships with the biliary and pancreatic ducts, and the presence of necrosis or intratumoral bleeding. Early lesions may be paucisymptomatic and identified incidentally. Symptomatic patients often report epigastric or left upper-quadrant pain, a sensation of heaviness, nausea and reduced appetite, with possible progressive weight loss.

Masses in the pancreatic head may cause obstructive jaundice, cholestasis and pruritus from compression of the main bile duct, with pale stools and dark urine. Body-tail lesions more often present with vague symptoms, pain radiating to the back and dyspepsia. Compression or invasion of vascular structures may cause edema, venous thrombosis or signs of segmental portal hypertension in selected settings, whereas growth toward the stomach or duodenum may be associated with postprandial symptoms and early satiety.

In histologic types with marked vascularity or vascular fragility, such as angiosarcoma, anemia, rapid deterioration in general condition and, more rarely, signs of internal bleeding may occur. Low-grade fever and elevated inflammatory indices may reflect tumor necrosis and do not necessarily indicate infection, although infectious complications may coexist in necrotic masses.

Clinical presentations that most often lead to dedicated pancreatic imaging

• Persistent epigastric pain or unexplained back pain.
• Unintentional weight loss, anorexia and worsening nausea.
• Cholestatic jaundice, especially in the presence of a mass in the pancreatic head.
• A palpable abdominal mass or a sensation of epigastric fullness.
• An incidental atypical pancreatic lesion on ultrasonography or CT performed for another reason.

Physical findings may be limited in early stages. Advanced disease may cause jaundice, tenderness, signs of malnutrition and, in metastatic disease, hepatomegaly or systemic signs related to dissemination. Clinical findings rarely distinguish sarcoma from pancreatic carcinoma, making the diagnostic sequence based on imaging and tissue sampling central.

The diagnostic pathway for primary pancreatic sarcomas begins with suspicion of a pancreatic mass and has three main objectives: accurately define the lesion and its vascular relationships, obtain a reliable histologic diagnosis with classification and grading, and correctly attribute the site of origin by distinguishing a pancreatic primary from secondary involvement or metastasis. The pretest probability of sarcoma is low, so suspicion arises mainly when imaging and clinical findings are discordant with typical patterns of ductal adenocarcinoma.

First-line investigations include general laboratory assessment and evaluation of cholestasis when present, with markers useful mainly for differential diagnosis rather than specific diagnosis. Epithelial markers such as CA 19-9 may be normal and do not exclude carcinoma, but a large mass with unremarkable markers may reinforce the need for tissue sampling. The reference imaging examination is pancreatic CT with a dedicated contrast-enhanced protocol, which assesses size, necrosis, vascularity, contiguity with adjacent organs and involvement of the superior mesenteric artery, celiac trunk, portal vein and superior mesenteric vein. MRI with cholangiopancreatography is particularly useful for characterizing solid and cystic components and hemorrhage and for evaluating the pancreatic and bile ducts.

The radiologic appearance of sarcomas is variable. Some lesions are large and heterogeneous, with central necrosis, relatively expansile margins and vascularity unlike that of hypovascular adenocarcinoma. No pattern is pathognomonic, however. Diagnosis therefore requires tissue. Endoscopic ultrasonography (EUS) with fine-needle aspiration or, preferably when available, core biopsy provides more adequate sampling for immunohistochemistry and molecular analyses. If EUS is not feasible or nondiagnostic, CT-guided percutaneous biopsy may be considered, balancing yield and complication risk according to location and needle trajectory.

Pathologic evaluation requires a panel-based approach. Epithelial, neuroendocrine, lymphoid and mesenchymal neoplasms are first distinguished, followed by classification of the sarcomatous subtype. Markers such as cytokeratins, synaptophysin/chromogranin, CD45 and specific panels for GIST (KIT, DOG1), smooth muscle (SMA, desmin), endothelium (CD31, ERG) and other lineages guide diagnosis. In lesions compatible with synovial sarcoma or extraosseous Ewing sarcoma, molecular confirmation of fusions is often decisive. Definition of grade, necrosis and proliferative index contributes to risk stratification and treatment selection.

A critical phase is attribution of primary pancreatic origin. The pancreas may harbor metastases from sarcomas arising elsewhere; retroperitoneal or gastric sarcomas may also secondarily involve the pancreas and mimic a primary tumor. Imaging should therefore include complete assessment of the chest, abdomen and pelvis, and the clinical history should search for previous sarcoma or masses at other sites. 18F-FDG PET may be useful to identify distant sites and guide biopsy of more accessible lesions, as well as to define extent in FDG-avid histologic types, although sensitivity varies.

In the absence of unique formalized international criteria for “primary pancreatic sarcoma,” reliable clinical attribution requires a set of converging elements integrating anatomy, pathology and systemic staging:

Essential elements for attributing a pancreatic primary site

• A lesion centered in the pancreas with radiologic features consistent with an intrapancreatic origin.
• Histologic diagnosis of sarcoma with immunohistochemistry and, when indicated, molecular confirmation of the histologic type.
• No clinical or radiologic evidence of a primary sarcoma elsewhere after complete staging.
• Multidisciplinary discussion with pathologic-radiologic review, especially when continuity with the retroperitoneum or stomach is possible.
• Adequate sampling to avoid a misleading diagnosis of undifferentiated carcinoma or a nonsarcomatous solid-cystic tumor.

In summary, diagnosis results from dedicated pancreatic imaging, tissue sampling with suitable material, immunohistochemical and molecular classification, and complete staging to define extent and primary site. This sequence is particularly important because treatment options and prognosis differ markedly among sarcoma subtypes and compared with more common pancreatic neoplasms.

Staging of primary pancreatic sarcomas is complex because the site is rare, histologic types are multiple, and staging systems commonly used for epithelial pancreatic tumors are inappropriate for a mesenchymal neoplasm. In clinical practice, assessment of extent is based on three axes: local disease and resectability in relation to vessels, distant dissemination and grade, a cross-cutting prognostic determinant in sarcoma.

In localized tumors, prognosis depends mainly on the ability to achieve complete resection with negative margins and on grade. Visceral sarcomas may recur locally or metastatically; risk increases with high grade, extensive necrosis, large size and invasion of vascular structures or contiguous organs. Nodal involvement is less frequent than in carcinomas, but when present it indicates biologically aggressive disease and influences treatment decisions.

In the absence of a dedicated system universally applied to the pancreatic site, a clinically useful and easily communicated stratification is based on anatomic disease distribution integrated with histologic grade. This classification does not replace formal sarcoma staging in general, but it guides immediate decisions and aligns follow-up with actual risk.

Clinical assessment of disease extent in primary pancreatic sarcomas

• Localized disease: lesion confined to the pancreas, without metastases, potentially resectable, with grading defined on an adequate specimen.
• Locally advanced disease: involvement of major vascular structures or contiguous organs making resection complex or unsafe, without distant metastases.
• Metastatic disease: visceral, peritoneal or bone metastases, with prognosis determined mainly by histologic type, disease burden and sensitivity to systemic treatment.

Overall prognosis is variable and depends critically on the histologic type. Tumors such as pancreatic angiosarcoma, when confirmed, are often highly aggressive, whereas some stromal forms amenable to targeted treatment follow different trajectories. In high-grade sarcomas, the risk of recurrence is substantial even after complete resection and mandates intensive surveillance. In young patients with fusion-defined tumors, response to chemotherapy may be more relevant, but rarity makes robust subtype-specific estimates difficult.

Important clinical indicators include performance status, nutritional status and comorbidities, which may deteriorate rapidly in pancreatic disease because of pain, anorexia and biliary complications. Nutritional stabilization and pain control have a practical effect on treatment tolerance and therefore outcome. Prognosis should be discussed cautiously and always anchored to histologic type, grade, resectability and documented metastases.

Treatment of primary pancreatic sarcomas requires a personalized approach based on histologic type, grade, extent and resectability, applying the principles used for visceral sarcomas and retroperitoneal tumors when appropriate. Given the rarity, the clinical objective is to maximize the quality of histologic diagnosis and concentrate decisions within a multidisciplinary setting because the same pancreatic mass may require radically different strategies depending on whether it is leiomyosarcoma, angiosarcoma, synovial sarcoma, extraosseous Ewing sarcoma or GIST/EGIST.

In resectable localized disease, surgery is the cornerstone. The procedure depends on location: pancreaticoduodenectomy for tumors of the head and distal resection for body-tail tumors, with or without splenectomy according to extension and vascular relationships. The central principle is to achieve negative surgical margins, because local control in sarcoma is closely linked to radicality. Unlike carcinomas, extended lymph-node dissection is not always a priority, but removal of suspicious nodes or relevant stations may be indicated for staging and local control, particularly in histologic types with greater nodal propensity.

Systemic therapy is considered according to histologic type and risk. In high-grade sarcomas or when major risk factors are present, perioperative chemotherapy may be discussed, although evidence specific to the pancreatic site is limited. In locally advanced disease, chemotherapy may be used for downstaging or progression control to make resection safer, whereas radiotherapy may be considered in selected settings for local control, taking into account the radiosensitivity of surrounding tissues and the risk of gastrointestinal toxicity.

A separate category consists of stromal neoplasms amenable to targeted therapies, such as GIST/EGIST, in which tyrosine-kinase inhibitors may be used neoadjuvantly to reduce tumor volume and surgical morbidity or in adjuvant and metastatic settings according to risk and mutation. Mutational definition guides treatment choice and sequence in these cases.

Treatment objectives according to the clinical setting

• Localized disease: complete resection with negative margins, systemic integration according to histologic type and risk, and early nutritional and functional recovery.
• Locally advanced disease: assessment of systemic treatment for control or conversion to resectability, with surgical reconsideration after a significant response.
• Metastatic disease: histology-directed systemic therapy, palliative procedures for local symptoms, and an integrated approach to pain and nutritional status.
• Targetable histologic types: molecular profiling and use of targeted drugs when indicated, with close monitoring of efficacy and toxicity.

In metastatic disease, systemic regimens are selected according to sarcoma principles: anthracyclines, ifosfamide and other combinations are considered according to histologic type and performance status, whereas strategies may differ for fusion-defined or driver-defined entities. Control of complications is often decisive. Obstructive jaundice, pain and malnutrition should be treated with supportive endoscopic or interventional procedures to permit access to oncologic therapy and reduce repeated hospital admissions.

Because of the intrinsic uncertainty associated with rarity, enrollment in clinical trials when available and management at dedicated sarcoma centers increase the likelihood of an accurate diagnosis and a treatment sequence consistent with the best available evidence for the subtype.

Follow-up for primary pancreatic sarcomas must be individualized because recurrence risk and pattern vary by histologic type, grade and surgical radicality. During the first years after curative-intent resection, recurrence risk is generally higher and requires closer surveillance integrating clinical assessment, laboratory tests directed at complications and periodic imaging.

The reference imaging examination is CT of the chest and abdomen because sarcomas tend to metastasize hematogenously, with lung involvement in many histologic types and possible hepatic or peritoneal sites. MRI may be useful in selected settings to better define local recurrence in the pancreatic or retroperitoneal region and assess the liver. 18F-FDG PET may be reserved for cases in which it helps clarify equivocal findings or assess response in FDG-avid histologic types.

Clinical surveillance includes attention to pain, weight loss, biliary symptoms, signs of exocrine pancreatic insufficiency and metabolic abnormalities. After pancreatic resection, assessment of digestive function and possible pancreatogenic diabetes is part of follow-up because it affects quality of life and treatment tolerance. In patients treated with chemotherapy or targeted agents, follow-up also includes early detection of toxicity and proactive adverse-event management.

In the absence of schedules dedicated to the pancreatic site, follow-up intensity is tailored to individual risk, with particular attention to high-grade sarcomas and cases with close or involved surgical margins, in which the probability of local recurrence is greater.

Long-term quality-of-life considerations in primary pancreatic sarcomas depend on the interaction among sequelae of pancreatic surgery, effects of systemic therapies and the psychological impact of a rare diagnosis. Even when disease control is achieved, daily life may be affected by digestive symptoms, dietary changes, the need for pancreatic enzyme replacement and metabolic monitoring.

After pancreatic resection, exocrine insufficiency may cause steatorrhea, bloating, weight loss and fat-soluble vitamin deficiencies, requiring pancreatic enzyme replacement and ongoing dietary support. Endocrine dysfunction may result in diabetes, requiring therapeutic education and diabetology follow-up. In patients undergoing major resections, reduced appetite and early satiety require stable reorganization of the diet into small, frequent meals, with clear nutritional goals to prevent sarcopenia.

Systemic therapies may leave chronic effects such as persistent fatigue, peripheral neuropathy, reduced exercise capacity or sleep disturbance. The impact varies with the regimen and treatment duration. Rehabilitation, pain management and psychological support have a practical role in improving follow-up adherence and reducing the social isolation that often accompanies complex oncologic pathways.

The rarity of the diagnosis amplifies uncertainty and fear of recurrence because patients often perceive the absence of a standard pathway. Clear communication about the rationale for decisions, continuity with a multidisciplinary team and access to psycho-oncology reduce psychological burden and promote more stable adjustment. In the long term, maintaining acceptable quality of life requires a balance among oncologic surveillance, management of pancreatic sequelae and attention to work and relationships.

Complications of primary pancreatic sarcomas arise from local progression, systemic dissemination and treatment effects. Locally, the mass may cause severe pain, biliary compression with jaundice and cholangitis, or duodenal compression with vomiting and reduced intake. Necrosis may cause low-grade fever and general deterioration; some vascular lesions may be associated with intralesional hemorrhage or anemia.

Distant dissemination may involve the liver, lung, peritoneum and bone, with organ-specific complications. Liver metastases may cause hepatic failure or ascites; peritoneal disease may cause abdominal pain, obstruction and nutritional deterioration; bone metastases may cause refractory pain and pathologic fractures. In high-grade sarcomas, progression may be rapid, making symptom control and preservation of function priorities.

Surgical complications include pancreatic fistula, infections, delayed gastric emptying, postoperative hemorrhage and venous thrombosis, with increased risk in malnourished patients or those with prolonged jaundice. Endoscopic or interventional procedures, including biopsies and drainage, carry risks of bleeding and pancreatitis that should be managed proactively.

• Chemotherapy toxicity in sarcoma: myelosuppression, nausea, fatigue, mucositis and, depending on the agents, cardiac or renal risk requiring dedicated monitoring.
• Toxicity from targeted agents when indicated: cutaneous, gastrointestinal, hepatic and cardiovascular events varying according to mechanism of action.
• Nutritional and metabolic complications: exocrine pancreatic insufficiency, pancreatogenic diabetes, vitamin deficiencies and sarcopenia, especially after extensive resection or with active disease.

Effective management of complications integrates correction of jaundice when present, pain control, early nutritional support, thromboembolic prophylaxis when appropriate and close monitoring during systemic therapies. In advanced stages, early integration of palliative care improves symptom control and reduces the care burden associated with repeated hospital admissions.